𝔖 Bobbio Scriptorium
✦   LIBER   ✦

811 Sequential high-dose therapy of adult acute lymphoblastic leukemia

✍ Scribed by J. Mehta; S. Singhal; J. Treleaven; C. Horton; R. Powles

Book ID
116167557
Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
149 KB
Volume
31
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The biology and therapy of adult acute l
The biology and therapy of adult acute lymphoblastic leukemia
✍ Stefan Faderl; Sima Jeha; Hagop M. Kantarjian πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 383 KB

## Abstract ## BACKGROUND Much progress has been made in understanding the biology of acute lymphoblastic leukemia (ALL). This has translated into the recognition of several subgroups of ALL and the institution of risk‐adapted therapies. New therapies are emerging based on the definition of specif

The use of higher dose clofarabine in ad
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia
✍ Bradley A. McGregor; Alexander W. Brown; Michael B. Osswald; Michael R. Savona πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 65 KB πŸ‘ 2 views

## Abstract The standard dose of clofarabine is 52 mg/m^2^ for pediatrics and 40 mg/m^2^ in adults. Clofarabine dosed at 52 mg/m^2^ was used in adult patients with refractory ALL to maximize response before allo‐HSCT. All patients had a significant response to therapy. Published pharmacokinetic ana

A single, high dose of idarubicin combin
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia
✍ Mark A. Weiss; Timothy B. Aliff; Martin S. Tallman; Stanley R. Frankel; Matt E. πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 79 KB

## Background: The majority of adult patients who are treated for lymphoblastic disease will either develop recurrent disease or will be refractory to their initial therapy. one option for patients with recurrent/refractory disease is to administer a reinduction regimen that employs a dose-intense